Cookie Policy

A full description of our cookie policy can be found here.

Essential (Required)

Cookies that the site cannot function without. This includes cookies for access to secure areas and CSRF protection. Please note that Craft's default cookies do not collect any personal or sensitive information. Craft's default cookies do not collect IP addresses. The information they store is not sent to Pixel & Tonic or any 3rd parties.

Name: CraftSessionId
Description: Craft relies on PHP sessions to maintain sessions across web requests. That is done via the PHP session cookie. Craft names that cookie “CraftSessionId” by default, but it can be renamed via the phpSessionName config setting. This cookie will expire as soon as the session expires.
Provider: biocatalysts.com
Expiry: Session

Name: *_identity
Description: When you log into the control panel, you’ll get an authentication cookie used to maintain your authenticated state. The cookie name is prefixed with a long, randomly generated string, followed by _identity. The cookie only stores information necessary to maintain a secure, authenticated session and will only exist for as long as the user is authenticated in Craft.
Provider: biocatalysts.com
Expiry: Persistent

Name: *_username
Description: If you check the "Keep me logged in" option during login, this cookie is used to remember the username for your next authentication.
Provider: biocatalysts.com
Expiry: Persistent

Name: CRAFT_CSRF_TOKEN
Description: Protects us and you as a user against Cross-Site Request Forgery attacks.
Provider: biocatalysts.com
Expiry: Session

BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25

BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biological solutions for industry, published its final financial figures for the first six months of fiscal year 2024/25

Published 28 May 2025

Home/ Media & Resources/ BRAIN Biotech AG reports final half-year figures for fiscal year 2024/25

BRAINBiocatalysts experienced modest organic growth in the first half of the year
BRAINBioIncubator with high basis for comparison in the previous year
Strong liquidity maintained at €14.9 million

BRAIN Biotech AG, a leading provider of specialty enzymes and innovative biological solutions for industry, published its final financial figures for the first six months of fiscal year 2024/25. BRAIN Biotech Group generated €25.2 million in revenue during the first half of the fiscal year, which is a 7.2 % decrease from the previous year (€27.2 million). This decline is primarily due to the subdued general economic environment and resulting delays in concluding new contracts for tailor-made solutions projects. Revenue fell by €2.4 million in the second quarter of 2024/25 compared to the previous year's period, dropping from €14.5 million to €12.1 million. This decline is due to the negative economic effects mentioned above and a one-time effect in the previous year: €1.5 million milestone payment for the clinical progress in developing the investigational pharmaceutical drug compound deucrictibant (formerly PHA 121).

“

Our enzyme-focused product business is performing comparatively better, though still below original expectations at the beginning of the year. We are currently focusing all our efforts on laying the groundwork for accelerated growth in the future and optimising our running costs

— Adriaan Moelker, CEO of BRAIN Biotech AG